Diabetologia (2012) 55:1971–1977 Table 2 Logistic regression for the ability to reach the metformin treatment target of HbA1c <7 % (53 mmol/mol) according to the ATM rs11212617 genotype Patients are included regardless of their baseline HbA1c. Additive logistic regression models were used to calculate the C-allelic OR in each cohort. Covariates included were baseline HbA1c, baseline gap (except DCS), daily dose, drug adherence (except for DCS and CARDS), and eGFR (except for CARDS and Rotter- dam Study). In the meta-analysis, a fixed-effects model was used Table 3 Linear regression for treatment HbA1c per ATM allele Patients are included regardless of their baseline HbA1c. An additive linear regression model was used to calculate the per C allele change in treatment HbA1c (%). Covariates included were baseline HbA1c, baseline gap (except DCS), daily dose, drug adherence (except for DCS and CARDS), and eGFR (except for CARDS and Rotterdam Study). The p value of the genotype effect is given. In the meta-analysis, a fixed-effects model was used Study Group n OR (95% CI) DCS Total group 929 1.27 (1.03, 1.58) Monotherapy 547 1.32 (0.99, 1.78) Dual therapy 382 1.20 (0.87, 1.66) Rotterdam Study Total group 182 1.44 (0.87, 2.39) Monotherapy 65 1.97 (0.72, 5.42) Dual therapy 117 1.40 (0.77, 2.57) CARDS Total group 254 1.03 (0.68, 1.57) Monotherapy 81 1.50 (0.76, 2.95) Dual therapy 173 0.82 (0.46, 1.46) Meta-analysis Total group 1,365 1.24 (1.04, 1.49) Monotherapy 693 1.38 (1.07, 1.80) Dual therapy 672 1.15 (0.89, 1.48) Meta-analysis including stage 2 replication cohorts previously used by Zhou et al [8] GoDARTS Total group 1,965 1.21 (1.05, 1.38) Monotherapy 1,460 1.25 (1.07, 1.46) Dual therapy 505 1.08 (0.84, 1.40) UKPDS Total group 1,113 1.37 (1.10, 1.72) Monotherapy 284 1.82 (1.20, 2.78) Dual therapy 829 1.23 (0.94, 1.62) Meta-analysis Total group 4,443 1.25 (1.13, 1.38) Monotherapy 2,437 1.33 (1.16, 1.50) Dual therapy 2,006 1.15 (0.99, 1.34) SE 0.14 0.19 0.19 0.36 0.19 0.30 0.21 0.34 0.29 0.09 0.13 0.13 0.07 0.08 0.13 0.11 0.21 0.14 0.05 0.07 0.08 Study Group n Beta (95% CI) DCS Total group 929 −0.020 (−0.095, 0.054) Monotherapy 547 0.026 (−0.065, 0.117) Dual therapy 382 −0.082 (−0.209, 0.045) Rotterdam Study Total group 182 −0.053 (−0.205, 0.098) Monotherapy 65 −0.107 (−0.327, 0.113) Dual therapy 117 −0.069 (−0.266, 0.127) CARDS Total group 254 0.163 (−0.031, 0.334) Monotherapy 81 −0.091 (−0.414, 0.213) Dual therapy 173 0.286 (0.089, 0.476) Meta-analysis Total group 1,365 0.001 (−0.061, 0.062) Monotherapy 693 −0.000 (−0.082, 0.081) Dual therapy 672 0.004 (−0.089, 0.098) Meta-analysis including stage 2 replication cohorts previously used by Zhou et al [8] GoDARTS Total group 1,965 −0.071 (−0.129, −0.014) Monotherapy 1,460 −0.080 (−0.147, −0.013) Dual therapy 505 −0.060 (−0.170, 0.050) UKPDS Total group 1,113 −0.123 (−0.228, −0.019) Monotherapy 284 −0.286 (−0.465, −0.107) Dual therapy 829 −0.067 (−0.193, 0.058) Meta-analysis Total group 4,443 −0.050 (−0.089, −0.010) Monotherapy 2,437 −0.066 (−0.116, −0.017) Dual therapy 2,006 −0.033 (−0.095, 0.029) SE 0.038 0.046 0.065 0.077 0.112 0.100 0.082 0.160 0.100 0.032 0.041 0.048 0.030 0.034 0.057 0.053 0.091 0.064 0.020 0.025 0.001 1975 p value 0.028 0.062 0.26 0.15 0.19 0.27 0.86 0.23 0.51 0.016 0.015 0.29 0.008 0.005 0.54 0.006 0.005 0.13 7.8 × 10−6 1.4 × 10−5 0.067 p value 0.59 0.58 0.21 0.49 0.33 0.49 0.06 0.54 0.005 0.99 0.99 0.92 0.016 0.020 0.29 0.021 0.001 0.30 0.013 0.009 0.29